Developer docs
API playgroundTry for free, no card

Search company profiles

Hofseth BioCare

Full company profile

uuid0002vry

Namestring
Hofseth BioCare
Legal namestring
Hofseth BioCare ASA
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Hofseth BioCare ASA is a Norwegian publicly listed specialty ingredients company (Oslo Stock Exchange: HBC) that converts salmon industry side streams into clinically validated bioactive health ingredients. The company's core technology upcycles salmon processing by-products into full spectrum omega-3 (OmeGo®) and salmon-derived bioactive peptides (ProGo®), serving nutraceutical manufacturers, pharmaceutical and cosmetic formulators, and the premium pet nutrition segment through its wholly owned Brilliant Petcare brand. Operations are anchored at the Midsund processing plant in Norway, which recorded its highest ever raw material throughput in 2025, with commercial offices in Oslo, London, Zürich, and Palo Alto supporting a multi-region B2B go-to-market.

The business operates across four revenue streams: direct B2B sales of bioactive ingredients to manufacturers, premium pet nutrition retail through Brilliant Petcare, licensing and supply agreements (notably the May 2026 exclusive ProGo® license to US-based Fission Holdings, which carries a USD 3 million minimum purchase commitment by January 2027 and is projected to exceed USD 5 million annually), and a 52%-owned US biotech subsidiary AecorBio Inc. that is developing lead candidate FT-002a for prostate cancer. Capital structure is supported by recurring equity raises (NOK 141 million in July 2022 and NOK 158 million in October 2025) and a CHF 3.5 million bond placement in May 2025, with proceeds directed toward B2B ingredients scaling, metabolic health and healthy aging product development, and expansion into Asia and the United States. Key shareholders include Guy Urquhart, Hofseth International AS, Aqua-Spark, Yokorei Co. Ltd., and Bonafide Wealth Management. Recent milestones include the April 2026 publication of head-to-head clinical trial data for OmeGo® demonstrating a >70% increase in Omega 3 Index over 14 weeks and 2.5x greater anti-inflammatory efficacy than concentrated fish oil comparators, alongside regulatory approvals in Australia and South Korea.

Short descriptiontext

Hofseth BioCare ASA is a Norwegian publicly listed specialty ingredients company that upcycles salmon industry side streams into clinically validated bioactive ingredients — OmeGo® omega-3 and ProGo® peptides — for nutraceutical, pharmaceutical, and premium pet nutrition customers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersÅlesund, Norway
HQ citystring
Ålesund
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
salmon bioactive ingredients, marine nutraceutical ingredients, omega-3 supplements, protein hydrolysates, pet nutrition ingredients
Industry3 codes
PRIMARYCRADAFAF
Functional & Veterinary Diet Pet Food
SECONDARYCRADAFAH
Natural/Organic & Limited-Ingredient Diets
SECONDARYHLAMAHAH
Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI)
Healthcare & Life Sciences/Veterinary & Animal Health/Animal Nutrition & Therapeutic Diets
NAICS code3 codes
  • Dog and Cat Food Manufacturing311111
  • Seafood Product Preparation and Packaging3117
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Prepared Fresh Or Frozen Fish & Seafoods2092
  • Fats & Oils2070
  • Biological Products, (No Disgnostic Substances)2836
Product category
Nutraceutical Ingredients
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1B2B Ingredients Sales
TypeTransaction Fee
Description

Sale of salmon-derived bioactive ingredients including OmeGo® omega-3 and ProGo® peptide ingredients to nutraceutical, pharmaceutical, and pet nutrition manufacturers worldwide.

ainvest.com
2Premium Pet Nutrition
TypeTransaction Fee
Description

Brilliant Petcare premium pet nutrition brand generates revenue through sale of finished pet health products targeting the premium pet nutrition market segment.

openpr.com
3Licensing and Supply Agreements
TypeLicensing Royalties
Description

Revenue from exclusive licensing agreements including ProGo® supply to Fission Holdings with minimum purchase commitments of $3 million annually, representing a new global route-to-market.

globenewswire.com
4Biotech Subsidiary Divestment
TypeTransaction Fee
Description

Partial divestment of AecorBio Inc. subsidiary at USD 36 million valuation, with HBC retaining 52% ownership while generating USD 5 million from share sale.

globenewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1OmeGo®
Description

Full spectrum omega-3 product that demonstrated clinical trial results showing increased Omega 3 Index by over 70% after 14 weeks, outperforming concentrated fish oil comparators.

globenewswire.com
+2 more records
Core offering1 text field

Hofseth BioCare ASA upcycles salmon industry side streams into bioactive health ingredients for human and pet nutrition. Its core offerings are OmeGo® full spectrum omega-3 and ProGo® salmon-derived bioactive peptide ingredients sold B2B to nutraceutical and pet nutrition manufacturers, complemented by the Brilliant Petcare premium pet nutrition brand.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 70%+ increase in Omega 3 Index after 14 weeks with OmeGo® product
+3 more records
Product overview1 text field

Hofseth BioCare ASA is a Norwegian consumer and pet health company that upcycles salmon industry side streams into health ingredients. The company operates a platform of salmon-derived bioactive ingredients spanning human nutrition (ProGo® peptide ingredient, OmeGo® omega-3 product) and premium pet nutrition (Brilliant Petcare brand). The portfolio also includes biotech subsidiary AecorBio Inc. focused on pharmaceutical applications. Operations span Oslo, London, Zürich, and Palo Alto with a processing plant in Midsund, Norway.

Product and service4 records
1ProGo®
2OmeGo®
CategoryOmega-3 nutraceutical ingredient
Description

Full spectrum omega-3 product derived from salmon, clinically proven to increase Omega 3 Index and reduce inflammatory markers linked to cardiovascular, metabolic, and cancer risks.

3Brilliant Petcare
4AecorBio Inc. (FT-002a)
CategoryPharmaceutical subsidiary
Description

US biotech subsidiary focused on pharmaceutical development of FT-002a for prostate cancer treatment; Hofseth BioCare retains approximately 52% ownership after partial divestment.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-22
Description

Exclusive License and Supply Agreement signed May 22, 2026 granting Fission Holdings worldwide rights to market, distribute, and sell HBC's ProGo® salmon-derived bioactive peptide ingredient through affiliate and network marketing channels. Fission is obligated to purchase minimum $3 million of ProGo® by January 31, 2027 to secure exclusivity, with projected annual sales exceeding $5 million.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

Strategic product partnership to develop performance nutrition products for athletes combining HBC's marine-based ingredients with Metabolic Elite's formulations. Focus areas include recovery, endurance, and metabolic health with emphasis on sustainability and natural resource utilization.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

US-based biotech subsidiary focused on pharmaceutical applications including FT-002a for prostate cancer treatment. HBC divested 1,616,498 shares for USD 5 million at USD 36 million valuation while retaining 52% ownership. Subsidiary shows promising preclinical results.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Norwegian-listed marine ingredient company producing krill-derived omega-3 and protein products for nutraceutical and aquaculture markets. Directly comparable business model of harvesting/processing marine raw materials into premium bioactive ingredients for human and animal nutrition.

TypeDirect peer
Description

Leading producer of marine-derived omega-3 EPA/DHA concentrates used in nutraceutical and pharmaceutical applications. Closely comparable as a B2B ingredient supplier focused on purified, high-concentration fish oil derivatives competing with Hofseth's full-spectrum positioning.

TypeDirect peer
Description

Norwegian refiner of marine oils producing omega-3 concentrates for supplements and functional food. Comparable as a Nordic marine ingredient manufacturer serving nutraceutical OEMs with value-added fish oil products.

4TripleNine (FF Skagen)
TypeDirect peer
Description

Danish producer of fish meal, fish oil, and protein hydrolysates from marine bycatch and side streams. Directly comparable upcycling model converting marine processing residues into protein and oil ingredients for feed and nutrition markets.

TypeDirect peer
Description

Leading omega-3 supplement brand sourcing marine oils for finished consumer health products. Comparable target customer base and product category (omega-3 supplementation), though positioned downstream as a finished brand rather than B2B ingredient supplier.

TypeBroad incumbent
Description

Global nutrition and health ingredients giant with broad omega-3, vitamin, and premix portfolios including marine-sourced ingredients for human and animal nutrition. Comparable as a large incumbent competing in the same ingredient categories HBC addresses.

TypeBroad incumbent
Description

Diversified chemical and ingredient manufacturer with omega-3 (including omega-3 from algae and fish) and animal nutrition product lines. Relevant broad incumbent in the nutritional ingredients space where HBC competes.

TypeBroad incumbent
Description

One of the largest global animal nutrition and aqua-feed producers with salmon-feed products through its EWOS business. Comparable as a major incumbent in salmon-adjacent nutrition, particularly relevant for HBC's pet nutrition and aquaculture side-stream strategy.

TypeBroad incumbent
Description

Major Norwegian-headquartered aquaculture feed manufacturer producing salmon feed with sustainability focus. Comparable upcycling and marine-protein themes, though serving the aquaculture feed segment rather than human nutraceuticals directly.

TypeEmerging player
Description

Specialty ingredient division of Symrise providing palatants and functional ingredients for the premium pet food industry. Comparable as a supplier of premium functional ingredients into the pet nutrition value chain that HBC's Brilliant Petcare competes within.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hofseth BioCare

Nutraceutical Ingredientshofsethbiocare.com

Hofseth BioCare ASA is a Norwegian publicly listed specialty ingredients company that upcycles salmon industry side streams into clinically validated bioactive ingredients — OmeGo® omega-3 and ProGo® peptides — for nutraceutical, pharmaceutical, and premium pet nutrition customers globally.

What Hofseth BioCare does

Hofseth BioCare ASA is a Norwegian publicly listed specialty ingredients company (Oslo Stock Exchange: HBC) that converts salmon industry side streams into clinically validated bioactive health ingredients. The company's core technology upcycles salmon processing by-products into full spectrum omega-3 (OmeGo®) and salmon-derived bioactive peptides (ProGo®), serving nutraceutical manufacturers, pharmaceutical and cosmetic formulators, and the premium pet nutrition segment through its wholly owned Brilliant Petcare brand. Operations are anchored at the Midsund processing plant in Norway, which recorded its highest ever raw material throughput in 2025, with commercial offices in Oslo, London, Zürich, and Palo Alto supporting a multi-region B2B go-to-market.

The business operates across four revenue streams: direct B2B sales of bioactive ingredients to manufacturers, premium pet nutrition retail through Brilliant Petcare, licensing and supply agreements (notably the May 2026 exclusive ProGo® license to US-based Fission Holdings, which carries a USD 3 million minimum purchase commitment by January 2027 and is projected to exceed USD 5 million annually), and a 52%-owned US biotech subsidiary AecorBio Inc. that is developing lead candidate FT-002a for prostate cancer. Capital structure is supported by recurring equity raises (NOK 141 million in July 2022 and NOK 158 million in October 2025) and a CHF 3.5 million bond placement in May 2025, with proceeds directed toward B2B ingredients scaling, metabolic health and healthy aging product development, and expansion into Asia and the United States. Key shareholders include Guy Urquhart, Hofseth International AS, Aqua-Spark, Yokorei Co. Ltd., and Bonafide Wealth Management. Recent milestones include the April 2026 publication of head-to-head clinical trial data for OmeGo® demonstrating a >70% increase in Omega 3 Index over 14 weeks and 2.5x greater anti-inflammatory efficacy than concentrated fish oil comparators, alongside regulatory approvals in Australia and South Korea.

Hofseth BioCare firmographics

Firmographics
Name
Hofseth BioCare
Legal name
Hofseth BioCare ASA
Website
https://hofsethbiocare.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Hofseth BioCare ASA is a Norwegian publicly listed specialty ingredients company that upcycles salmon industry side streams into clinically validated bioactive ingredients — OmeGo® omega-3 and ProGo® peptides — for nutraceutical, pharmaceutical, and premium pet nutrition customers globally.
Ownership category
akta.pro rank

Hofseth BioCare industry classification

Industry
Product category
Nutraceutical Ingredients
NAICS
Dog and Cat Food Manufacturing (311111), Seafood Product Preparation and Packaging (3117), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Prepared Fresh Or Frozen Fish & Seafoods (2092), Fats & Oils (2070), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYCRADAFAF
Functional & Veterinary Diet Pet Food
SECONDARYCRADAFAH
Natural/Organic & Limited-Ingredient Diets
SECONDARYHLAMAHAH
Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI)
Healthcare & Life Sciences/Veterinary & Animal Health/Animal Nutrition & Therapeutic Diets

Keywords

  • Salmon bioactive ingredients
  • Marine nutraceutical ingredients
  • Omega-3 supplements
  • Protein hydrolysates
  • Pet nutrition ingredients

Where Hofseth BioCare is headquartered

Location

Headquarters

HQ city
Ålesund
HQ country
Norway
HQ region
Europe

Offices6 records

Markets served

Hofseth BioCare business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. B2B Ingredients Sales: Sale of salmon-derived bioactive ingredients including OmeGo® omega-3 and ProGo® peptide ingredients to nutraceutical, pharmaceutical, and pet nutrition manufacturers worldwide.
  2. Premium Pet Nutrition: Brilliant Petcare premium pet nutrition brand generates revenue through sale of finished pet health products targeting the premium pet nutrition market segment.
  3. Licensing and Supply Agreements: Revenue from exclusive licensing agreements including ProGo® supply to Fission Holdings with minimum purchase commitments of $3 million annually, representing a new global route-to-market.
  4. Biotech Subsidiary Divestment: Partial divestment of AecorBio Inc. subsidiary at USD 36 million valuation, with HBC retaining 52% ownership while generating USD 5 million from share sale.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Hofseth BioCare product offering

Product offering

Core offering

Hofseth BioCare ASA upcycles salmon industry side streams into bioactive health ingredients for human and pet nutrition. Its core offerings are OmeGo® full spectrum omega-3 and ProGo® salmon-derived bioactive peptide ingredients sold B2B to nutraceutical and pet nutrition manufacturers, complemented by the Brilliant Petcare premium pet nutrition brand.

Product overview

Hofseth BioCare ASA is a Norwegian consumer and pet health company that upcycles salmon industry side streams into health ingredients. The company operates a platform of salmon-derived bioactive ingredients spanning human nutrition (ProGo® peptide ingredient, OmeGo® omega-3 product) and premium pet nutrition (Brilliant Petcare brand). The portfolio also includes biotech subsidiary AecorBio Inc. focused on pharmaceutical applications. Operations span Oslo, London, Zürich, and Palo Alto with a processing plant in Midsund, Norway.

Differentiator

Problem solved

Functional benefit

Brands

  • OmeGo®: Full spectrum omega-3 product that demonstrated clinical trial results showing increased Omega 3 Index by over 70% after 14 weeks, outperforming concentrated fish oil comparators.
  • ProGo®
  • Brilliant Petcare

Products and services

  • ProGo®
  • OmeGo® Full spectrum omega-3 product derived from salmon, clinically proven to increase Omega 3 Index and reduce inflammatory markers linked to cardiovascular, metabolic, and cancer risks.
  • Brilliant Petcare
  • AecorBio Inc. (FT-002a) US biotech subsidiary focused on pharmaceutical development of FT-002a for prostate cancer treatment; Hofseth BioCare retains approximately 52% ownership after partial divestment.

Quantifiable outcome

  • 70%+ increase in Omega 3 Index after 14 weeks with OmeGo® product
  • +3 more outcomes

Companies that use Hofseth BioCare

Customer profile

Segments4 records

Ideal customer profiles4 records

Hofseth BioCare technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Hofseth BioCare partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Fission Holdings LLCflagshipChannel Partner/ Reseller/ Distributor · 22 May 2026Exclusive License and Supply Agreement signed May 22, 2026 granting Fission Holdings worldwide rights to market, distribute, and sell HBC's ProGo® salmon-derived bioactive peptide ingredient through affiliate and network marketing channels. Fission is obligated to purchase minimum $3 million of ProGo® by January 31, 2027 to secure exclusivity, with projected annual sales exceeding $5 million.
  • Metabolic Elite / Jim LaVallecoreStrategic or Co-development Partner · 20 November 2025Strategic product partnership to develop performance nutrition products for athletes combining HBC's marine-based ingredients with Metabolic Elite's formulations. Focus areas include recovery, endurance, and metabolic health with emphasis on sustainability and natural resource utilization.
  • AecorBio Inc.coreStrategic or Co-development PartnerUS-based biotech subsidiary focused on pharmaceutical applications including FT-002a for prostate cancer treatment. HBC divested 1,616,498 shares for USD 5 million at USD 36 million valuation while retaining 52% ownership. Subsidiary shows promising preclinical results.

Scale indicators12 records

Recent moves8 records

Expansion highlights7 records

Hofseth BioCare competitors and assessment

Company assessment

Direct peers

  • Aker BioMarine: Norwegian-listed marine ingredient company producing krill-derived omega-3 and protein products for nutraceutical and aquaculture markets. Directly comparable business model of harvesting/processing marine raw materials into premium bioactive ingredients for human and animal nutrition.
  • Epax (Pelagia): Leading producer of marine-derived omega-3 EPA/DHA concentrates used in nutraceutical and pharmaceutical applications. Closely comparable as a B2B ingredient supplier focused on purified, high-concentration fish oil derivatives competing with Hofseth's full-spectrum positioning.
  • GC Rieber Oils: Norwegian refiner of marine oils producing omega-3 concentrates for supplements and functional food. Comparable as a Nordic marine ingredient manufacturer serving nutraceutical OEMs with value-added fish oil products.
  • TripleNine (FF Skagen): Danish producer of fish meal, fish oil, and protein hydrolysates from marine bycatch and side streams. Directly comparable upcycling model converting marine processing residues into protein and oil ingredients for feed and nutrition markets.
  • Nordic Naturals: Leading omega-3 supplement brand sourcing marine oils for finished consumer health products. Comparable target customer base and product category (omega-3 supplementation), though positioned downstream as a finished brand rather than B2B ingredient supplier.

Broad incumbents

  • DSM-Firmenich: Global nutrition and health ingredients giant with broad omega-3, vitamin, and premix portfolios including marine-sourced ingredients for human and animal nutrition. Comparable as a large incumbent competing in the same ingredient categories HBC addresses.
  • BASF Animal Nutrition: Diversified chemical and ingredient manufacturer with omega-3 (including omega-3 from algae and fish) and animal nutrition product lines. Relevant broad incumbent in the nutritional ingredients space where HBC competes.
  • Cargill Animal Nutrition: One of the largest global animal nutrition and aqua-feed producers with salmon-feed products through its EWOS business. Comparable as a major incumbent in salmon-adjacent nutrition, particularly relevant for HBC's pet nutrition and aquaculture side-stream strategy.
  • BioMar: Major Norwegian-headquartered aquaculture feed manufacturer producing salmon feed with sustainability focus. Comparable upcycling and marine-protein themes, though serving the aquaculture feed segment rather than human nutraceuticals directly.

Emerging players

  • Symrise Diana Pet Food: Specialty ingredient division of Symrise providing palatants and functional ingredients for the premium pet food industry. Comparable as a supplier of premium functional ingredients into the pet nutrition value chain that HBC's Brilliant Petcare competes within.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Hofseth BioCare social profiles

Digital presence

Hofseth BioCare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hofseth BioCare leadership team

Management profile

Number of profiles

Profiles2 records

Hofseth BioCare subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Hofseth BioCare funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hofseth BioCare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hofseth BioCare

What does Hofseth BioCare do?

Hofseth BioCare ASA upcycles salmon industry side streams into bioactive health ingredients for human and pet nutrition. Its core offerings are OmeGo® full spectrum omega-3 and ProGo® salmon-derived bioactive peptide ingredients sold B2B to nutraceutical and pet nutrition manufacturers, complemented by the Brilliant Petcare premium pet nutrition brand.

Is Hofseth BioCare a public or private company?

Hofseth BioCare is a public company. It is classified as public and is currently operating.

When was Hofseth BioCare founded?

Hofseth BioCare was founded in 2009. It employs 11 to 50 people.

Where is Hofseth BioCare based?

Hofseth BioCare is headquartered in Ålesund, Norway, in the Europe region.

How does Hofseth BioCare make money?

Four revenue lines are on record. B2B Ingredients Sales are the primary driver. The others are premium Pet Nutrition, licensing and Supply Agreements and biotech Subsidiary Divestment.

Who are Hofseth BioCare's main competitors?

Direct peers on record are Aker BioMarine, Epax (Pelagia), GC Rieber Oils, TripleNine (FF Skagen) and Nordic Naturals. Broad incumbents are DSM-Firmenich, BASF Animal Nutrition, Cargill Animal Nutrition and BioMar. Symrise Diana Pet Food is listed as an emerging player.

Does Hofseth BioCare have an API?

No public API is recorded for Hofseth BioCare.

What industry is Hofseth BioCare in?

Hofseth BioCare's product category is Nutraceutical Ingredients. Its primary akta.pro industry code is CRADAFAF, Functional & Veterinary Diet Pet Food, with a secondary code of CRADAFAH, Natural/Organic & Limited-Ingredient Diets. Its NAICS code is 311111 and its SIC code is 2092.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialHofseth Biocare ASA: THIRD QUARTER 2026 FINANCIAL REPORTHofseth Biocare reported Q3 2026 revenue of NOK 83.5 million, up 54.9% year-on-year, with EBITDA turning positive at NOK 4.4 million. Cash and equivalents fell to NOK 33.6 million, and the company expects trial initiation for its ProGo menopause study in Q4 2026.GlobeNewswireHofseth BioCare ASA: THIRD QUARTER 2026 FINANCIAL REPORTHofseth BioCare reported Q3 2026 operating revenue of NOK 83.5 million, up from NOK 54.9 million a year earlier, the highest quarterly revenue. EBITDA turned positive at NOK 4.4 million, and cash fell NOK 80.6 million to NOK 33.6 million. The company expects the ProGo menopause study to start in Q4 2026.TradingViewHofseth BioCare ASA: THIRD QUARTER 2026 FINANCIAL REPORTHofseth BioCare reported Q3 2026 operating revenue of NOK 83.5 million, up from NOK 54.9 million a year earlier, the highest quarterly total. EBITDA turned positive at NOK 4.4 million, and pet nutrition revenue rose 39.5% year-on-year to NOK 35.2 million. The company expects the ProGo menopause study to initiate in Q4 2026.TradingViewHofseth BioCare ASA (HBC) Q3 Revenue Rose to NOK 83.5MHofseth BioCare ASA reported Q3 2026 operating revenue of NOK 83.5M, up from NOK 54.9M a year earlier, with EBITDA turning positive to NOK 4.4M from a negative NOK 21.1M. Cash fell NOK 80.6M to NOK 33.6M, raising liquidity concerns. Further positive EBITDA and updated liquidity disclosures would clarify sustainability.The future of tradingHofseth BioCare Issues 237,500 Shares as Board Remuneration for First Half of 2026Hofseth BioCare issued 237,500 ordinary shares on November 5, 2026, as board remuneration for the first half of 2026. Linda Christin Hoff received 50,000 shares, while five other recipients each received 37,500 shares. The awards follow shareholders' June 30 decision to pay annual board remuneration through ordinary shares.The future of tradingHofseth BioCare ASA: PRIMARY INSIDER NOTIFICATIONHofseth BioCare ASA's board increased share capital by NOK 2,375, issuing 237,500 shares to board members for first-half 2026 remuneration. The allocation triggers primary insider notifications for five named insiders, including Linda Christin Hoff and Amy Bennett Novogratz.YahooHofseth BioCare ASA: PRIMARY INSIDER NOTIFICATIONHofseth BioCare ASA's board issued 237,500 shares to board members for the first half of 2026 remuneration, including 50,000 shares to Linda Christin Hoff. The issuance was authorized by the general meeting and triggers a primary insider notification.GlobeNewswireHofseth BioCare ASA: PRIMARY INSIDER NOTIFICATIONHofseth BioCare ASA's board increased share capital by NOK 2,375, issuing 237,500 shares to board members for first-half 2026 remuneration. Primary insiders received allocations, including 50,000 shares for Linda Christin Hoff. The allocation triggers a primary insider notification under EU and Norwegian law.Business & FinancialHofseth Biocare ASA Resolution To Increase The Share CapitalHofseth Biocare's board resolved on 5 November 2026 to increase share capital by NOK 2,375 via issuance of 237,500 shares to board members as remuneration. After registration, the company's share capital will be NOK 5,224,731.38, divided into 506,473,138 ordinary shares and 16,000,000 preference shares.YahooHofseth BioCare ASA – Resolution to increase the share capitalHofseth BioCare ASA's board increased share capital by NOK 2,375, issuing 237,500 shares to board members as remuneration for the first half of 2026. The company's share capital now stands at NOK 5,224,731.38, divided into 506,473,138 ordinary shares and 16,000,000 preference shares.